X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Fulford India Fact Sheet, Fulford India Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Fulford India Fact Sheet   (FLFD)

Here is the latest financial fact sheet of Fulford India. For more details, see the Fulford India quarterly results and Fulford India share price and chart. For a sector overview, read our pharmaceuticals sector report.

FULFORD INDIA Price History

Price Rs 2,362.0
Mkt Cap Rs m 9,212
Vol '000 3.3
P/E X 398.8
P/CF X 153.8
EPS (TTM) Rs 5.9
% ch % 0.0
No. of shares m 3.90
% ch week % 0.9
% ch 1-mth % 5.3
% ch 12-mth % 44.0
52 week H/L Rs 2,365.0/1,100.0
(As on Jul 30, 2015 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

FULFORD INDIA Financials

No. of Mths
Year Ending
12
Dec-09
*
12
Dec-10
*
12
Dec-11
*
12
Dec-12
*
15
Mar-14
*
5-Yr Chart
Click to enlarge
FULFORD INDIA EQUITY SHARE DATA
High Rs8441,2731,064958942 
Low Rs272787389452450 
Sales per share (Unadj.) Rs471.5487.7549.2552.2691.4 
Earnings per share (Unadj.) Rs34.530.94.7-12.811.5 
Diluted earnings per shareRs34.530.94.7-12.811.5 
Cash flow per share (Unadj.) Rs37.335.09.1-8.415.4 
Dividends per share (Unadj.) Rs4.504.503.501.002.00 
Adj. dividends per shareRs4.504.503.501.002.00 
Dividend yield (eoy) %0.80.40.50.10.3 
Book value per share (Unadj.) Rs358.6384.2384.9370.9380.0 
Adj. book value per shareRs358.6384.2384.9370.9380.0 
Shares outstanding (eoy) m3.903.903.903.903.90 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x1.22.11.31.31.0 
Avg P/E ratio x16.233.3154.0-55.160.7 
P/CF ratio (eoy) x15.029.579.8-83.645.3 
Price / Book Value ratio x1.62.71.91.91.8 
Dividend payout %13.014.674.2-7.817.4 
Avg Mkt Cap Rs m2,1764,0182,8332,7502,714 
No. of employees `0000.40.50.50.50.4 
Total wages/salary Rs m286332420451505 
Avg. sales/employee Rs Th4,132.63,850.24,284.04,524.66,073.0 
Avg. wages/employee Rs Th642.2671.5839.0947.31,137.4 
Avg. net profit/employee Rs Th302.7243.936.8-104.8100.7 
FULFORD INDIA INCOME DATA
Net Sales Rs m1,8391,9022,1422,1542,696 
Other income Rs m68799497125 
Total revenues Rs m1,9071,9812,2362,2502,822 
Gross profit Rs m166114-49-152-46 
Depreciation Rs m1116171715 
Interest Rs m031010 
Profit before tax Rs m22317427-7354 
Minority Interest Rs m00000 
Prior Period Items Rs m-20000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m86539-2310 
Profit after tax Rs m13512118-5045 
Gross profit margin %9.06.0-2.3-7.0-1.7 
Effective tax rate %38.630.731.931.217.7 
Net profit margin %7.36.30.9-2.31.7 
FULFORD INDIA BALANCE SHEET DATA
Current assets Rs m1,5481,8411,9201,7251,738 
Current liabilities Rs m367424616513545 
Net working cap to sales %64.274.560.956.244.3 
Current ratio x4.24.33.13.43.2 
Inventory Days Days7163767648 
Debtors Days Days292216114 
Net fixed assets Rs m5655422712 
Share capital Rs m3939393939 
"Free" reserves Rs m1,3591,4591,4621,4081,443 
Net worth Rs m1,3981,4991,5011,4471,482 
Long term debt Rs m00000 
Total assets Rs m1,7661,9232,1622,0092,077 
Interest coverage xNM61.039.6-180.36.7 
Debt to equity ratio x00000 
Sales to assets ratio x1.01.01.01.11.3 
Return on assets %7.66.40.9-2.52.6 
Return on equity %9.68.01.2-3.43.0 
Return on capital %15.811.81.8-5.04.3 
Exports to sales %00000 
Imports to sales %36.628.536.532.924.5 
Exports (fob) Rs m00000 
Imports (cif) Rs m673542781708659 
Fx inflow Rs m001917 
Fx outflow Rs m1,097558812727673 
Net fx Rs m-1,097-558-811-718-656 
FULFORD INDIA CASH FLOW
From Operations Rs m -45 60 112 -266 90 
From Investments Rs m 7 180 78 85 105 
From Financial Activity Rs m -9 -23 -21 -16 -14 
Net Cashflow Rs m -47 216 169 -198 181 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

FULFORD INDIA Raw Materials Data

ITEM Rs m % To R.M.C. % To SALES
Antibiotics 20.0 89.3 0.7
Others 2.4 10.7 0.1

Share Holding

Indian Promoters 0.0%
Foreign collaborators 75.0%
Indian inst/Mut Fund 3.8%
FIIs 0.1%
ADR/GDR 0.0%
Free float 21.2%
Shareholders 4,783
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF Platina, 8th Floor, Plot No. C-59, G-Block, B. K. C, Bandra (E), Mumbai-400 098
E-MAIL sachin.gaikwad@merck.com WEB www.fulfordindia.com
TELEPHONE (022) 6789 8888 FAX (022) 6789 8889
SECTOR PHARMACEUTICALS GROUP M N C
TR AGENT Link Intime India, C13, Pannalal Silk Mills Compd., LBS Marg, Mumbai-78
AUDITOR Lovelock & Lewes
CHM: Ajit Dangi COMP SEC: Sachin A. Gaikwad YEAR OF INC: 1948 BSE CODE: 506803 FV (Rs): 10 DIV YIELD (%): 0.1

More Pharmaceuticals Company Fact Sheets:   INDRAPRASTHA MEDICAL  GLENMARK PHARMA  AUROBINDO PHARMA  NOVARTIS  FRESENIUS KABI ONCO.  

Compare FULFORD INDIA With:   INDRAPRASTHA MEDICAL  GLENMARK PHARMA  AUROBINDO PHARMA  NOVARTIS  FRESENIUS KABI ONCO.  

Compare FULFORD INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day in Red; Pharma Stocks Lose Most(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Views on news

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FULFORD INDIA

FULFORD INDIA - ALEMBIC PHARMA COMPARISON

COMPARE FULFORD INDIA WITH

MARKET STATS